Iron, Alpha-Synuclein, and Lymphocyte-activation Gene-3 in Ischemic Stroke
NCT ID: NCT05748587
Last Updated: 2024-06-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
48 participants
OBSERVATIONAL
2023-04-01
2024-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Is there an association between iron and alpha-synuclein accumulation in ischemic stroke?
* Is there any change in soluble lymphocyte activation gene levels in ischemic stroke and if these levels are related to stroke severity and infarction size? . Can soluble lymphocyte activation gene levels be used as an early biomarker to diagnose ischemic stroke?
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of HC-58 in Upper Limb Hemiplegic Patients After Stroke
NCT01623622
Hypoalbuminemia in Mild Acute Stroke and Cognitive Impariment Post-stroke
NCT04135872
The Screening of Neuroprotective Biomarkers After Acute Ischemic Stroke
NCT05689528
Different Treatment Strategies on Prognosis of Acute Ischemic Stroke(AISDTS)
NCT05410457
Efficacy and Safety of Ferrous Iron on the Prevention of Vascular Cognitive Impairment Among Patients With Cerebral Infarction/TIA (FAVORITE)
NCT03891277
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
24 healthy age and sex-matched controls
Serum Iron
Serum iron levels in study groups
RBCs Alpha-synuclein
α-syn levels in RBCs
Serum Soluble lymphocyte activation gene
sLAG-3 in the serum of study groups
Brain computed tomography
Brain CT of patients after admission
Patients with acute Ischemic stroke
24 patients between 50-70 years having neurological symptoms of acute ischemic stroke will be included.
Patients with acute hemorrhagic stroke, Parkinson's disease, dementia, Alzheimer's disease, malignancy, and central nervous system infection will be excluded.
Serum Iron
Serum iron levels in study groups
RBCs Alpha-synuclein
α-syn levels in RBCs
Serum Soluble lymphocyte activation gene
sLAG-3 in the serum of study groups
Brain computed tomography
Brain CT of patients after admission
Control rats
8 rats will be subjected to a Sham operation and will be injected intramuscularly immediately after the operation with an equivalent 0.9% saline solution. After 24 hours they will be sacrificed.
Brain Iron
Iron in brain homogenate of rats
Brain Alpha-synuclein
α-syn expression in rat's brain
Brain lymphocyte activation gene
LAG-3 expression in rat's brain
Rats with ischemic stroke
8 rats will be subjected to bilateral common carotid artery occlusion (CCAO) for 30 minutes and will be injected intramuscularly immediately after removing the occlusion with an equivalent 0.9% saline solution. They will be sacrificed after 24 hours of reperfusion.
Brain Iron
Iron in brain homogenate of rats
Brain Alpha-synuclein
α-syn expression in rat's brain
Brain lymphocyte activation gene
LAG-3 expression in rat's brain
Rats with ischemic stroke + deferoxamine
8 rats will be subjected to bilateral CCAO for 30 minutes and will be injected intramuscularly immediately after removing the occlusion with deferoxamine (200 mg/kg), They will be sacrificed after 24 hours of reperfusion.
Brain Iron
Iron in brain homogenate of rats
Brain Alpha-synuclein
α-syn expression in rat's brain
Brain lymphocyte activation gene
LAG-3 expression in rat's brain
Deferoxamine
intramuscular deferoxamine (200 mg/kg) injection to rats
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Serum Iron
Serum iron levels in study groups
RBCs Alpha-synuclein
α-syn levels in RBCs
Serum Soluble lymphocyte activation gene
sLAG-3 in the serum of study groups
Brain computed tomography
Brain CT of patients after admission
Brain Iron
Iron in brain homogenate of rats
Brain Alpha-synuclein
α-syn expression in rat's brain
Brain lymphocyte activation gene
LAG-3 expression in rat's brain
Deferoxamine
intramuscular deferoxamine (200 mg/kg) injection to rats
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients having neurological symptoms of acute ischemic stroke.
Exclusion Criteria
2. Patients with Parkinson's disease (PD).
3. Patients with dementia, and Alzheimer's disease.
4. Patients with any type of malignancy.
5. Patients with central nervous system infection.
50 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aswan University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Asmaa Abdel-mageed Muhammed
Lecturer
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Asmaa Abdelmageed Muhammed
Role: PRINCIPAL_INVESTIGATOR
Aswan University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aswan University Hospital
Aswān, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Malfertheiner K, Stefanova N, Heras-Garvin A. The Concept of alpha-Synuclein Strains and How Different Conformations May Explain Distinct Neurodegenerative Disorders. Front Neurol. 2021 Oct 5;12:737195. doi: 10.3389/fneur.2021.737195. eCollection 2021.
Wu Q, Wei C, Guo S, Liu J, Xiao H, Wu S, Wu B, Liu M. Acute iron overload aggravates blood-brain barrier disruption and hemorrhagic transformation after transient focal ischemia in rats with hyperglycemia. IBRO Neurosci Rep. 2022 Jul 3;13:87-95. doi: 10.1016/j.ibneur.2022.06.006. eCollection 2022 Dec.
Yoon CW, Park HK, Bae EK, Rha JH. Sleep Apnea and Early Neurological Deterioration in Acute Ischemic Stroke. J Stroke Cerebrovasc Dis. 2020 Feb;29(2):104510. doi: 10.1016/j.jstrokecerebrovasdis.2019.104510. Epub 2019 Nov 22.
Zhao L, Wang H, Xu K, Liu X, He Y. Update on lymphocyte-activation gene 3 (LAG-3) in cancers: from biological properties to clinical applications. Chin Med J (Engl). 2022 May 20;135(10):1203-1212. doi: 10.1097/CM9.0000000000001981.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
sLAG-3 in brain ischemia
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.